Next Article in Journal
Carbon Ion Radiobiology
Previous Article in Journal
Tailored Exercise during Hematopoietic Stem Cell Transplantation Hospitalization in Children with Cancer: A Prospective Cohort Study
cancers-logo
Article Menu

Article Menu

Open AccessArticle

Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab

1
Department of Gynecology and Obstetrics, Heidelberg University Hospital, 69120 Heidelberg, Germany
2
National Center for Tumor Diseases, Heidelberg University Hospital, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
3
Department of Obstetrics and Gynecology, University of Tübingen, 72076 Tübingen, Germany
4
Department of Gynecology and Obstetrics, Erlangen University Hospital, Comprehensive Cancer Center Erlangen-EMN, Friedrich Alexander University of Erlangen-Nuremberg, 91054 Erlangen, Germany
5
Department of Gynecology and Obstetrics, Marienhospital Bottrop, 46236 Bottrop, Germany
6
Frankfurt Center for Bone Health, 60313 Frankfurt am Main, Germany
7
Oncology Practice, Bethanien Hospital, 60389 Frankfurt am Main, Germany
8
Biostatistics Unit, Department of Gynecology and Obstetrics, Erlangen University Hospital, 91054 Erlangen, Germany
9
Department of Obstetrics and Gynecology, Klinikum rechts der Isar, Technical University of Munich, 81675 Munich, Germany
10
Department of Hematology, Oncology and Tumor Immunology, Charité University Hospital, Campus Benjamin Franklin, 12203 Berlin, Germany
11
Department of Gynecology, Hamburg-Eppendorf University Medical Center, 20246 Hamburg, Germany
12
ClinSol GmbH & Co KG, 97074 Würzburg, Germany
13
Ansbach University of Applied Sciences, 91522 Ansbach, Germany
14
Department of Gynecology and Obstetrics, Carl Gustav Carus Faculty of Medicine and University Hospital, Technical University of Dresden, 01307 Dresden, Germany
15
National Center for Tumor Diseases (NCT), Partner Site Dresden, Carl Gustav Carus Faculty of Medicine and University Hospital, Technical University of Dresden, Helmholtz-Zentrum Dresden-Rossendorf (HZDR), 01328 Dresden, Germany
16
German Cancer Consortium (DKTK), Dresden and German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
17
g.SUND Gynäkologie-Onkologisches Zentrum, 18435 Stralsund, Germany
18
Department of Gynecology and Obstetrics, Klinik Hohe Warte, 95445 Bayreuth, Germany
19
Department of Gynecology I (Gynecologic Oncology), Gynecologic Center Bonn-Friedensplatz, 53111 Bonn, Germany
20
Department of Gynecology and Obstetrics, Breast Center and CCC Munich, Munich University Hospital, 81377 Munich, Germany
21
Department of Gynecology and Obstetrics, Helios Clinics Berlin-Buch, 13125 Berlin, Germany
22
OncoConsult Overkamp GmbH, 10557 Berlin, Germany
23
Department of Gynecology and Obstetrics, Ulm University Hospital, 89075 Ulm, Germany
24
Department of Gynecology, Zurich University Hospital, 8091 Zurich, Switzerland
25
Kooperatives Brustzentrum Paderborn, Department of Gynecology and Obstetrics, Frauenklinik St. Louise, Paderborn, St. Josefs-Krankenhaus, Salzkotten, 33098 Paderborn, Germany
26
Department of Gynecology and Obstetrics, Düsseldorf University Hospital, 40225 Düsseldorf, Germany
*
Author to whom correspondence should be addressed.
Cancers 2020, 12(10), 3021; https://doi.org/10.3390/cancers12103021
Received: 21 August 2020 / Revised: 2 October 2020 / Accepted: 7 October 2020 / Published: 17 October 2020
Data about the efficacy of trastuzumab emtansine (T-DM1) following pertuzumab treatment is limited due to the simultaneous development of the two drugs. Thus, the aim of this study was to investigate the efficacy of T-DM1 after previous treatment with pertuzumab in a large, real-world group of patients. We showed that the progression-free survival (PFS) in patients treated with T-DM1 after pertuzumab was 3.5 months. T-DM1 was mainly administered second-line after pertuzumab. The PFS in higher therapy lines appears to be shorter than in second-line ones. In summary, this study provides evidence that T-DM1 has clinically reasonable activity after prior pertuzumab treatment, with a median PFS period of approximately 3–4 months. It appears to be recommendable to administer T-DM1 in earlier therapeutic lines.
The approval of trastuzumab emtansine (T-DM1) was conducted without pertuzumab as previous therapy. Efficacy data on T-DM1 following pertuzumab treatment are therefore limited. This study explores this issue in a real-world setting. Within the prospective PRAEGNANT (Prospective Academic Translational Research Network for the Optimization of the Oncological Health Care Quality in the Advanced Setting) metastatic breast cancer registry (NCT02338167), patients in all therapy lines receiving any kind of treatment were eligible for inclusion. This report describes patient characteristics and progression-free survival (PFS) in human epidermal growth factor receptor 2 (HER2)-positive patients receiving T-DM1 after pertuzumab treatment. Seventy-six patients were identified, 39 of whom received T-DM1 as second-line therapy, 25 as third-line, and 12 as fourth-line therapy or higher. Pertuzumab was mostly administered as a first-line treatment (n = 61; 80.3%). The median PFS in all patients was 3.5 months (95% CI: 2.8–7.8); in second-line treatment, 7.7 months (95% CI: 2.8–11.0); in third-line, 3.4 months (95% CI: 2.3–not reached (NR)); and in fourth-line therapy or higher, 2.7 months (95% CI: 1.2–NR). T-DM1 was mainly administered second-line after pertuzumab, but also in more heavily pretreated patients. The PFS in higher therapy lines appears to be shorter than in second-line. View Full-Text
Keywords: advanced breast cancer; metastatic; chemotherapy; HER2 c-erbB2; HER2/neu; trastuzumab; pertuzumab; T-DM1 advanced breast cancer; metastatic; chemotherapy; HER2 c-erbB2; HER2/neu; trastuzumab; pertuzumab; T-DM1
Show Figures

Figure 1

MDPI and ACS Style

Michel, L.L.; Hartkopf, A.D.; Fasching, P.A.; Kolberg, H.-C.; Hadji, P.; Tesch, H.; Häberle, L.; Ettl, J.; Lüftner, D.; Wallwiener, M.; Müller, V.; Beckmann, M.W.; Belleville, E.; Volz, B.; Huebner, H.; Wimberger, P.; Hielscher, C.; Mundhenke, C.; Kurbacher, C.; Wuerstlein, R.; Untch, M.; Overkamp, F.; Huober, J.; Janni, W.; Taran, F.-A.; Lux, M.P.; Wallwiener, D.; Brucker, S.Y.; Schneeweiss, A.; Fehm, T.N. Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers 2020, 12, 3021.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop